A multicenter study of primary brain tumor incidence in Australia (2000-2008) There are conflicting reports from Europe and North America regarding trends in the incidence of primary brain tumor, whereas the incidence of primary brain tumors in Australia is currently unknown. We aimed to determine the incidence in Australia with age-, sex-, and benign-versus-malignant histology-specific [...]
Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas–an assessment of 3 new variables in predicting clinical outcome Although pilocytic astrocytoma (PA) is the most common brain tumor diagnosed in children, few prognostic variables have been delineated that stratify the risk of clinical progression in patients with this tumor. In this study, the MIB-1 [...]
Nilotinib alone or in combination with selumetinib is a drug candidate for neurofibromatosis type 2 Loss of the tumor suppressor merlin is a cause of frequent tumors of the nervous system, such as schwannomas, meningiomas, and ependymomas, which occur spontaneously or as part of neurofibromatosis type 2 (NF2). Because there is medical need for drug [...]
Establishment and characterization of clinically relevant models of ependymoma: a true challenge for targeted therapy The development of new therapies for ependymoma is dramatically limited by the absence of optimal in vivo and in vitro models. Successful ependymoma treatment requires a profound understanding of the disease’s biological characteristics. This study focuses on the establishment and [...]
Acorda Therapeutics Licenses Rights To Investigational Treatment For Spinal Cord Injury And Traumatic Brain Injury Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has licensed worldwide development and commercialization rights to a proprietary magnesium formulation from Medtronic, Inc. (NYSE: MDT), which will be referred to as AC105… No tags for this post.
